Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis
Antibodies, Monoclonal, Murine-Derived
Glomerulosclerosis, Focal Segmental
Rituximab can be used with caution as a treatment for recFSGS. Efficacy is variable from none to complete response. Even partial reduction in proteinuria is of benefit in prolonging the life of the allograft. Long-term, multicenter studies are needed to prove its sustained efficacy in those who respond and to monitor for serious adverse effects.